Register for our free email digests:
MediStem gets IP from Yale University for use in cell therapies for Type I diabetes
- Gene Therapy, Cell Therapy
- R+D and Marketing-Licensing
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.